Skip to main content

Advertisement

SpringerLink
Log in

A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The purpose of this study was to evaluate the efficacy and safety of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in hormone-responsive, premenopausal, operable breast cancer. One hundred and nineteen patients with hormone-responsive, premenopausal, operable breast cancer were enrolled in the study. Zoladex at 3.6 mg was given by subcutaneous injection every 4 weeks for 3 cycles. CEF (cyclophosphamide, 600 mg/m2, epirubicin, 60–90 mg/m2, and fluorouracil 500 mg/m2) was administered every 3 weeks for 4 cycles as neoadjuvant therapy. The primary objective was a pathologic complete response (PCR) rate in the breast. Thirty-one patients (26.1%) achieved a clinical complete response, and 76 patients (63.9%) achieved a clinical partial response; the clinical response rate was 90.0%. Fourteen patients (11.8%) achieved a pathologic complete response (T0/Tis, N0), and 20 patients (16.8%) achieved a pathologic complete response (T0/Tis, Nx). When stratified by the clinical lymph node status, the clinical partial response rate in the clinical lymph node negative group was significantly higher than in the clinical lymph node positive group (P = 0.02). When stratified by hormonal status, the clinical partial response rate in the ER and PR + group was significantly better than the ER or PR− group (P = 0.0471). There were no treatment-related deaths and no grades 3 or 4 toxicity. The most common adverse event was nausea (grade 1 65.5%, grade 2 18.5%), vomiting (grade 1 58.8%, grade 2 13.4%), and alopecia (grade 1 45.4%, grade 2 54.6%). Zoladex combined with CEF chemotherapy was effective as neoadjuvant therapy in hormone-responsive, premenopausal breast cancer. This regimen was particularly effective in the clinical lymph node negative group and in the ER/PR double positive group. (ClinicalTrials.gov number, NCT00488722).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000;321:624–8.

    Article  PubMed  CAS  Google Scholar 

  2. Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005;14:243–50.

    Article  PubMed  Google Scholar 

  3. Gradishar W. Landmark trials in endocrine adjuvant therapy for breast carcinoma. Cancer. 2006;106:975–81.

    Article  PubMed  Google Scholar 

  4. Rody A, Loibl S, von Minckwitz G, et al. Use of goserelin in the treatment of breast cancer. Expert Rev Anticancer Ther. 2005;5:591–604.

    Article  PubMed  CAS  Google Scholar 

  5. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex early breast cancer research association study. J Clin Oncol. 2002;20:4628–35.

    Article  PubMed  CAS  Google Scholar 

  6. Fogelman I, on behalf of the ZEBRA Trialists’ Group. Assessment of bone mineral density in pre-/perimenopausal women treated with Zoladex TM versus CMF adjuvant terapy for management of nodepositive, early breast cancer: results from the ZEBRA study. Breast. 2001;10(Suppl 1): S31, Abstr P59.

  7. de Haes H, Olschewswki M, Schumaker M, et al. Early benefits in quality of life (Qol) observed in Zoladex TM—treated versus CMF-treated pre-/perimenopaysal patients with node-positive early breast cancer. Proc ASCO. 2001;20:35a,Abstr138.

    Google Scholar 

  8. Name M, Jonat W, Kaufman M, et al. Survial data from the ZEBRA study. Ann Oncol. 2002;13(suppl 5):38, Abstr 135P.

    Google Scholar 

  9. Castiglinoe-Gertsch M, O’Neill A, Gelber RD, et al. Is the addition of adjuvant chemotherapy always necessary in node negative(N-) pre/perimenopaysal breast cancer patients (pts) who receive goserelin? First results of IBCSG trial VIII. Proc ASCO. 2002;21:38a, Abstr 149.

  10. Castiglione-Gertsch M, Gelber RD, O’Neill A, et al. Systemic adjuvant treatment for premenopausal node-negative breast cancer. Eur J Cancer. 2000;36:549–50.

    Article  PubMed  CAS  Google Scholar 

  11. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer–Austrian breast and colorectal cancer study group trial 5. J Clin Oncol. 2002;20:4621–7.

    Article  PubMed  CAS  Google Scholar 

  12. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the italian breast cancer adjuvant study group 02 randomized trial. J Clin Oncol. 2000;18:2718–27.

    PubMed  CAS  Google Scholar 

  13. Boccardo F, Rubagotti A, Amoroso D, et al. CMF versus tamoxifen (TAM) plus ovarian suppres sion (OS) as adjuvant treatment of ER-positive (ER+) pre/perimenopausal breast cancer (BCA) patients(pts). Breast. 2001;10(Suppl 1):S32, Abstr P62.

    Google Scholar 

  14. Kuter I. Breast cancer highlights. Oncologist. 1999;4:299–308.

    PubMed  CAS  Google Scholar 

  15. Bianco AR, Costanzo R, Di Lorenzo G, et al. The Mam-1 GOCSI trial: a randomised trial with factorial design of chemo-endocrine adjuvant treatment in node-positive (N+) early breast cancer (ebc). Proc ASCO. 2001;20:27a, Abstr 104.

  16. Liu ZY, Zhang J. Comparison clinical effect of TE versus CEF regimens as neoadjuvant chemotherapy in the treatment of breast cancer. Chin J Breast Cancer. 2008;2:30–9.

    CAS  Google Scholar 

  17. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–71.

    Article  PubMed  CAS  Google Scholar 

  18. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, Benítez J, Palacios J. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol. 2007;60:1006–12.

    Article  PubMed  Google Scholar 

  19. Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006;42:3149–56.

    Article  PubMed  CAS  Google Scholar 

  20. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell. 2007;1:241–2.

    Article  PubMed  CAS  Google Scholar 

  21. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–61.

    Article  PubMed  CAS  Google Scholar 

  22. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. 3rd Department of Breast Cancer, Tianjin Medical University Cancer Hospital, West Beihuanhu Rd., 300060, Tianjin, People’s Republic of China

    Sheng Zhang, Jingjing Liu & Jin Zhang

  2. Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, People’s Republic of China

    Sheng Zhang, Jingjing Liu & Jin Zhang

  3. Key Laboratory of Cancer Prevention and Therapy in Tianjin, Tianjin, People’s Republic of China

    Sheng Zhang, Jingjing Liu & Jin Zhang

  4. Department of Breast Cancer, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, No.127 Dongming Rd, 450003, Zhengzhou, People’s Republic of China

    Chongjian Zhang, Li Qin & Shude Cui

Authors
  1. Sheng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chongjian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jingjing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shude Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Shude Cui or Jin Zhang.

Additional information

Sheng Zhang and Chongjian Zhang contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, S., Zhang, C., Liu, J. et al. A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer. Med Oncol 29, 479–485 (2012). https://doi.org/10.1007/s12032-011-9883-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9883-2

Keywords

Search

Navigation